Context-dependent differences in miR-10b breast oncogenesis can be targeted for the prevention and arrest of lymph node metastasis.

Oncogene
Mehmet V YigitZ Medarova

Abstract

Metastases, and not the primary tumor from which they originate, are the main reason for mortality from carcinoma. Although the molecular mechanisms behind metastasis are poorly understood, it is clear that epigenetic dysregulation at the level of microRNA expression is a key characteristic of the metastatic process that can be exploited for therapy. Here, we describe an miRNA-targeted therapeutic approach for the prevention and arrest of lymph node metastasis. Therapy relies on the inhibition of the pro-metastatic microRNA-10b. It is delivered to primary and lymph node metastatic tumor cells using an imaging-capable nanodrug that is designed to specifically home to these tissues. Treatment of invasive human breast tumor cells (MDA-MB-231) with the nanodrug in vitro downregulates miR-10b and abolishes the invasion and migration of the tumor cells. After intravenous delivery to mice bearing orthotopic MDA-MB-231-luc-D3H2LN tumors, the nanodrug accumulates in the primary tumor and lymph nodes. When treatment is initiated before metastasis to lymph nodes, metastasis is prevented. Treatment after the formation of lymph node metastases arrests the metastatic process without a concomitant effect on primary tumor growth raising the po...Continue Reading

References

Nov 16, 2002·Proceedings of the National Academy of Sciences of the United States of America·George Adrian CalinCarlo M Croce
Feb 8, 2003·Trends in Biotechnology·Michael Petersen, Jesper Wengel
Jun 20, 2003·The New England Journal of Medicine·Mukesh G HarisinghaniRalph Weissleder
Aug 6, 2004·Oligonucleotides·Jan Stenvang JepsenJesper Wengel
Feb 27, 2007·Nature Medicine·Zdravka MedarovaAnna Moore
Apr 5, 2007·Nature Protocols·Zdravka MedarovaAnna Moore
Jun 19, 2007·Cancer Research·Yingshe ZhaoPhilippe Clézardin
Jan 18, 2008·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Ambros J BeerMarkus Schwaiger
Feb 8, 2008·Cell Cycle·Li Ma, Robert A Weinberg
Mar 28, 2008·Nature·Joacim ElménSakari Kauppinen
May 17, 2008·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Laura M KennyEric O Aboagye
Aug 5, 2008·Trends in Genetics : TIG·Li Ma, Robert A Weinberg
Jan 15, 2009·Cancer Research·Zdravka MedarovaAnna Moore
Jul 14, 2009·The Journal of Pathology·Raffaele BaffaAnne Rosenberg
Aug 7, 2009·Annals of Surgical Oncology·S David NathansonDhananjay Chitale
Sep 30, 2009·PloS One·Derek M DykxhoornJudy Lieberman
Feb 23, 2010·Nature Cell Biology·Li MaRobert A Weinberg
Mar 31, 2010·Nature Biotechnology·Li MaRobert A Weinberg
Aug 13, 2010·Cancer Research·Mohanraja KumarZdravka Medarova
Mar 26, 2011·Science·Christine L Chaffer, Robert A Weinberg
Apr 8, 2011·Cancer Research·Galina GabrielyAnna M Krichevsky
Jul 29, 2011·Autophagy·Galina GabrielyAnna M Krichevsky

❮ Previous
Next ❯

Citations

Feb 11, 2014·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Umar RazaOzgür Sahin
Feb 4, 2016·Chemical Communications : Chem Comm·Muhit RanaMehmet V Yigit
Oct 11, 2015·Biotechnology Advances·Anuradha SubramanianSwaminathan Sethuraman
May 20, 2015·Molecular Imaging and Biology : MIB : the Official Publication of the Academy of Molecular Imaging·Byunghee YooZdravka Medarova
Mar 6, 2016·Biosensors & Bioelectronics·Neil M RobertsonMehmet V Yigit
Jul 22, 2014·Wiley Interdisciplinary Reviews. RNA·Neil M Robertson, Mehmet V Yigit
Aug 26, 2015·Langmuir : the ACS Journal of Surfaces and Colloids·Neil M RobertsonMehmet V Yigit
Oct 1, 2013·Journal of Controlled Release : Official Journal of the Controlled Release Society·Yu ZhangRichard A Gemeinhart
Dec 3, 2014·Advanced Drug Delivery Reviews·Huiyuan WangYongzhuo Huang
May 8, 2014·Journal of Controlled Release : Official Journal of the Controlled Release Society·Gemma M RyanChristopher J H Porter
Apr 15, 2016·Chemical Communications : Chem Comm·Irfan KhanMaksim Royzen
Mar 4, 2015·Bioconjugate Chemistry·Neil M RobertsonMehmet V Yigit
Jan 21, 2014·Chemistry & Biology·Byunghee YooZdravka Medarova
Oct 21, 2014·PloS One·Wenjing ZhangIrene M Ghobrial
Oct 27, 2016·ACS Applied Materials & Interfaces·Yunfei LiChengfeng Yang
Apr 4, 2017·Journal of Cellular Biochemistry·Maryam KeshavarziHamed Mirzaei
Jan 10, 2018·Frontiers in Oncology·Byunghee YooZdravka Medarova
Jun 20, 2018·Nanoscale·Elisabetta AvitabileLucia Gemma Delogu
Jan 4, 2019·Journal of Cellular Physiology·Homa MollaeiZeinab Rostami
Jan 29, 2016·Oncology Reports·Ai-Ling LiangYong-Jun Liu
Mar 23, 2017·Scientific Reports·Byunghee YooZdravka Medarova
Mar 2, 2017·The Journal of Clinical Investigation·Brian D AdamsFrank J Slack
Jun 28, 2016·Oncology Letters·Yunfeng WangZhihai Peng
Jul 26, 2018·Frontiers in Oncology·Byunghee YooZdravka Medarova
Aug 10, 2016·PloS One·Xiu ChenJin-Hai Tang
Mar 20, 2019·Scientific Reports·Byunghee YooZdravka Medarova
Dec 7, 2013·Journal of Materials Chemistry. B, Materials for Biology and Medicine·Mustafa BalciogluMehmet V Yigit
Feb 4, 2021·Scientific Reports·Byunghee YooZdravka Medarova
Mar 26, 2021·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Yu-Long Lan, Jianmin Zhang
Jan 12, 2015·ACS Biomaterials Science & Engineering·Mustafa BalciogluMehmet V Yigit

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.